| XALIA LEA- Xarelto® for Long-term and Initial Anticoagulation in VenousThromboembolism (VTE) in Latin America,EMEA and Asia |
Ongoing |
Rivaroxaban |
4 |
17237 |
King Fahad Medical City (Riyadh), King Fahad Hospital (Madinah), King Faisal Hospital (Taif), Hira Hospital (Makkah) |
| Efficacy of Different Mouthwashes in the Reduction of Halitosis: A Randomized, Double Blind, Placebo-Controlled, Crossover Clinical Trial |
Ongoing |
Halita - AO ProRinse |
4 |
PR oo39 |
College of Dentistry King Saud University |
| Early Goal Directed Sedation vs. Standard Care Sedation |
Ongoing |
Dexmedetomidine |
4 |
YS/003 |
King Saud Medical City (Riyadh) |
| Observational Prospective STudy In Management of 1st line KRAS Wildtype mCRC with Erbitux™ (Cetuximab)- OPTIM1SE |
Ongoing |
Erbitux (Cetuximab) |
4 |
EMR062202-561 |
King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), Prince Sultan Military Medical City (Riyadh), King Fahad Specialist Hospital (Dammam) |
| easypod connect: A regional, Multicentre, Observational study to evaluate Adherenceand Long Term Outcomes of Therapy in Paediatric subjects using “easypodTM” electromechanical device for growth hormone treatment |
Ongoing |
N/A |
4 |
EMR200104-534 |
King Fahad University Hospital (Al-Khobar), alhabib |
| AWARE-AMAC (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation in Asia pacific, Middle-east and African Countries (AWARE-AMAC): A noninterventional study to collect data on the management and clinical impacts of chronic urticaria in patients refractory to H1-antihistamine therapy |
Ongoing |
N/A |
4 |
E3401 |
King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah) |
| Postoperative Analgesic Effect ofDexmedetomidine as an Adjunct to Ropivacaine Administration in Wound Infiltration for Modified Radical Mastectomy- A Randomized controlled Trial |
Ongoing |
DEXMEDETOMIDINE |
2 |
14-119 |
King Abdullah Medical City (Makkah) |
| CogniPlus Study assessing Cognitive performance plus Physical activity in patients with Relapsing-Remitting MS under treatment with Betaferon® |
Ongoing |
Betaferon |
4 |
16036 |
King Fahad Hospital (Madinah), Security Forces Hospital (Riyadh), Aseer Central Hospital, King Khalid University Hospital (Riyadh), Al-Noor Specialist Hospital (Makkah), King Abdul Aziz Specialist hospital (Taif), King Fahad Specialist Hospital (Dammam) |
| Non transfusion dependent Thalassemia Drug Registry |
Ongoing |
Exjade (Deferasirox) |
4 |
E2422 |
King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Khalid University Hospital (Riyadh) |
| A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer |
Ongoing |
LEE011 (Ribociclib) |
3 |
CLEE011E2301 |
King Khalid University Hospital (Riyadh)_ King Faisal Specialist Hospital and Research Center (Riyadh) |
